Bioventus (BVS) Net Income towards Common Stockholders (2020 - 2026)

Bioventus' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 218.78% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.5 million (up 1139.8% YoY) and the FY2023 annual result came in at -$74.4 million, down 8.28% from the prior year.
• Net Income towards Common Stockholders was $3.9 million for Q1 2026 at Bioventus, down from $17.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $17.3 million in Q4 2025 and bottomed at -$74.4 million in Q2 2023.
• A 4-year average of -$11.2 million and a median of -$340500.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 93484.0% — and 2026, when it jumped 218.78%.
• Bioventus' Net Income towards Common Stockholders stood at -$23.4 million in 2022, then slumped by 218.13% to -$74.4 million in 2023, then surged by 123.27% to $17.3 million in 2025, then tumbled by 77.21% to $3.9 million in 2026.
• Business Quant data shows BVS's Net Income towards Common Stockholders at $3.9 million in Q1 2026, $17.3 million in Q4 2025, and $4.0 million in Q3 2025.